WO2006105374A3 - Optimizing pharmacodynamics of therapeutic agents for treating vascular tissue - Google Patents

Optimizing pharmacodynamics of therapeutic agents for treating vascular tissue Download PDF

Info

Publication number
WO2006105374A3
WO2006105374A3 PCT/US2006/011850 US2006011850W WO2006105374A3 WO 2006105374 A3 WO2006105374 A3 WO 2006105374A3 US 2006011850 W US2006011850 W US 2006011850W WO 2006105374 A3 WO2006105374 A3 WO 2006105374A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmacodynamics
optimizing
therapeutic agents
vascular tissue
treating vascular
Prior art date
Application number
PCT/US2006/011850
Other languages
French (fr)
Other versions
WO2006105374A2 (en
Inventor
Andrew J Carter
Original Assignee
Andrew J Carter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andrew J Carter filed Critical Andrew J Carter
Priority to EP06740159A priority Critical patent/EP1874281A4/en
Publication of WO2006105374A2 publication Critical patent/WO2006105374A2/en
Publication of WO2006105374A3 publication Critical patent/WO2006105374A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures

Abstract

An implant such as a stent is coated with a biodegradable or non-biodegradable polymer having therein an antiproliferative/immunosuppressive agent and a compound which reduces the rate of metabolism of the antiproliferative/immunosuppressive agent thereby inhibiting restenosis.
PCT/US2006/011850 2005-03-30 2006-03-30 Optimizing pharmacodynamics of therapeutic agents for treating vascular tissue WO2006105374A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06740159A EP1874281A4 (en) 2005-03-30 2006-03-30 Optimizing pharmacodynamics of therapeutic agents for treating vascular tissue

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/096,241 US20060222627A1 (en) 2005-03-30 2005-03-30 Optimizing pharmacodynamics of therapeutic agents for treating vascular tissue
US11/096,241 2005-03-30

Publications (2)

Publication Number Publication Date
WO2006105374A2 WO2006105374A2 (en) 2006-10-05
WO2006105374A3 true WO2006105374A3 (en) 2007-02-01

Family

ID=37054163

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/011850 WO2006105374A2 (en) 2005-03-30 2006-03-30 Optimizing pharmacodynamics of therapeutic agents for treating vascular tissue

Country Status (3)

Country Link
US (1) US20060222627A1 (en)
EP (1) EP1874281A4 (en)
WO (1) WO2006105374A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090074831A1 (en) * 2007-09-18 2009-03-19 Robert Falotico LOCAL VASCULAR DELIVERY OF mTOR INHIBITORS IN COMBINATION WITH PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR STIMULATORS
WO2010017432A1 (en) * 2008-08-07 2010-02-11 Schering Corporation Pharmaceutical formulations of an hcv protease inhibitor in a solid molecular dispersion
ES2897473T3 (en) 2013-03-15 2022-03-01 Biosensors Int Group Ltd Purification of rapamycin derivatives
CN110384854B (en) * 2019-08-02 2020-12-01 上海心玮医疗科技有限公司 Drug balloon with controllable drug metabolism and preparation method thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020980A1 (en) * 1994-02-02 1995-08-10 The Regents Of The University Of California Method for increasing bioavailability of oral pharmaceutical compositions
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US20010041706A1 (en) * 2000-03-24 2001-11-15 Synold Timothy W. Blockade of taxane metabolism
US6706691B1 (en) * 1998-07-15 2004-03-16 Board Of Regents, The University Of Texas System Immunosupportive drug sparing diet
US20050031713A1 (en) * 2003-08-06 2005-02-10 Elliot Ehrich Methods for administering active agents to CYP3A4 sensitive patients

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515016B2 (en) * 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
GB2325934A (en) * 1997-06-03 1998-12-09 Polybiomed Ltd Treating metal surfaces to enhance bio-compatibility and/or physical characteristics
DE50210591D1 (en) * 2001-02-16 2007-09-13 Abbott Lab Vascular Entpr Ltd IMPLANTS WITH FK506 FOR RESTENOSIS TREATMENT AND PROPHYLAXIS
WO2003034944A1 (en) * 2001-10-15 2003-05-01 Hemoteq Gmbh Coating of stents for preventing restenosis
US20060121080A1 (en) * 2002-11-13 2006-06-08 Lye Whye K Medical devices having nanoporous layers and methods for making the same
EP1635815A4 (en) * 2003-06-03 2009-03-25 Beth Israel Hospital Methods and compounds for the treatment of vascular stenosis
US20050064005A1 (en) * 2003-08-13 2005-03-24 Dinh Thomas Q. Active agent delivery systems including a miscible polymer blend, medical devices, and methods
CA2536042A1 (en) * 2003-11-10 2005-06-02 Angiotech International Ag Medical implants and anti-scarring agents
AU2005272790A1 (en) * 2004-08-13 2006-02-23 Setagon, Inc. Medical devices having nanoporous layers and methods for making the same
WO2006036982A2 (en) * 2004-09-28 2006-04-06 Atrium Medical Corporation Drug delivery coating for use with a stent
US20060135562A1 (en) * 2004-11-16 2006-06-22 Boehringer Ingelheim International Gmbh Method for treating HIV infection through co-administration of tipranavir and darunavir

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020980A1 (en) * 1994-02-02 1995-08-10 The Regents Of The University Of California Method for increasing bioavailability of oral pharmaceutical compositions
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US6706691B1 (en) * 1998-07-15 2004-03-16 Board Of Regents, The University Of Texas System Immunosupportive drug sparing diet
US20010041706A1 (en) * 2000-03-24 2001-11-15 Synold Timothy W. Blockade of taxane metabolism
US20050031713A1 (en) * 2003-08-06 2005-02-10 Elliot Ehrich Methods for administering active agents to CYP3A4 sensitive patients

Also Published As

Publication number Publication date
WO2006105374A2 (en) 2006-10-05
EP1874281A2 (en) 2008-01-09
US20060222627A1 (en) 2006-10-05
EP1874281A4 (en) 2009-01-14

Similar Documents

Publication Publication Date Title
WO2007139931A3 (en) Bioabsorbable stent with radiopaque coating
WO2007126606A3 (en) Controlled degradation and drug release in stents
MX2009012766A (en) Absorbable stent having a coating for controlling degradation of the stent and maintaining ph neutrality.
WO2008002632A3 (en) Carbon coating on an implantable device
WO2006110197A3 (en) Polymer biodegradable medical device
WO2008057344A3 (en) Coated surgical mesh
WO2007084361A3 (en) Coated medical devices and methods of making the same
EP1795215A3 (en) Absorbable stent comprising coating for controlling degradation and maintaining pH neutrality
WO2008051579A3 (en) Temporal intraluminal stent, methods of making and using
WO2007111811A3 (en) Corrosion resistant coatings for biodegradable metallic implants
WO2005121264A3 (en) Poly(ester amide) coating composition for implantable devices
MX2009005405A (en) Intraocular drug delivery systems.
WO2008002586A3 (en) Coatings for medical devices comprising a therapeutic agent and a metallic material
WO2008034048A3 (en) Bioerodible endoprosthesis with biostable inorganic layers
WO2010079218A3 (en) Drug-eluting medical device
WO2008016696A3 (en) Composite polymeric and metallic stent with radiopacity
WO2006047289A3 (en) Angiotensin-(1-7) eluting polymer-coated medical device to reduce restenosis and improve endothelial cell function
WO2007024472A3 (en) USE OF PAR- l/PAR- 4 INHIBITORS FOR TREATING OR PREVENTING VASCULAR DISEASES
WO2006002399A3 (en) Biodegradable implantable medical devices, methods and systems
BR0213279A (en) Stent coating to prevent restenosis
WO2010021757A3 (en) Implantable medical device coatings with biodegradable elastomer and releasable taxane agent
WO2007139845A3 (en) Systems and methods for introducing and applying a bandage structure within a body lumen or hollow body organ
WO2008087488A3 (en) Expandable medical device for the treatment and prevention of cardiovascular diseases
WO2004069201A3 (en) Compounds useful in coating stents to prevent and treat stenosis and restenosis
WO2004000379A8 (en) Stent coatings with sustained drug release rate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006740159

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU